OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 15:38 UTC. Every row links to its source record.

BCOR BCL6 corepressor

ENSG00000183337 · protein coding · Open Targets profile

Transcriptional corepressor. May specifically inhibit gene expression when recruited to promoter regions by sequence-specific DNA- binding proteins such as BCL6 and MLLT3. This repression may be mediated at least in part by histone deacetylase activities which can associate with this corepressor. Involved in the repression of TFAP2A; impairs binding of BCL6 and KDM2B to TFAP2A promoter regions. Via repression of TFAP2A acts as a negative regulator of osteo-dentiogenic capacity in adult stem cells; the function implies inhibition of methylation on histone H3 'Lys-4' (H3K4me3) and 'Lys-36' (H3K36me2). {ECO:0000269|PubMed:10898795, ECO:0000269|PubMed:15004558, ECO:0000269|PubMed:18280243, ECO:0000269|PubMed:19578371, ECO:0000269|PubMed:23911289}.

In 15 of 15 cancers, the evidence for BCOR comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751endometrial cancerendometrial cancerendometrial cancer: somatic 0.80acute myeloid leukemiaacute myeloid leukemiaacute myeloid leukemia: somatic 0.58acute myeloid leukemia: germline 0.55gastric adenocarcinomagastric adenocarcinomagastric adenocarcinoma: somatic 0.58B-cell chronic lymphocytic leukemiaB-cell chronic lymphocytic leukemiaB-cell chronic lymphocytic leukemia: somatic 0.57colorectal adenocarcinomacolorectal adenocarcinomacolorectal adenocarcinoma: somatic 0.54retinoblastomaretinoblastomaretinoblastoma: somatic 0.61skin basal cell carcinomaskin basal cell carcinomaskin basal cell carcinoma: somatic 0.61cutaneous melanomacutaneous melanomacutaneous melanoma: somatic 0.61endometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinomaendometrial endometrioid adenocarcinoma: somatic 0.61lymphoid neoplasmlymphoid neoplasmlymphoid neoplasm: somatic 0.61carcinoma of liver and intrahepatic bil…carcinoma of liver and intrahepatic biliary tractcarcinoma of liver and intrahepatic biliary tract: somatic 0.61B-cell prolymphocytic leukemiaB-cell prolymphocytic leukemiaB-cell prolymphocytic leukemia: somatic 0.61rectal tubular adenomarectal tubular adenomarectal tubular adenoma: somatic 0.61ovarian endometrioid adenocarcinoma wit…ovarian endometrioid adenocarcinoma with squamous differentiationovarian endometrioid adenocarcinoma with squamous differentiation: somatic 0.61Transitional MeningiomaTransitional MeningiomaTransitional Meningioma: somatic 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
High-Quality Ligand
PROTAC
UniProt Ubiquitination, Database Ubiquitination, Small Molecule Binder

gnomAD loss of function constraint: o/e 0.11539000272750854 (upper bound 0.19573000073432922). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of BCOR's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of BCOR's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.